跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
RYLAZE - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
RYLAZE
Authorized
STANDARD
RYLAZE
JAZZ PHARMACEUTICALS IRELAND LIMITED
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
29251e4d80f51d93
Company
JAZZ PHARMACEUTICALS IRELAND LIMITED
Type
Standard
Approval Details
Approval Id
29251e4d80f51d93
Drug Approval Canada Name
RYLAZE
Product Name
RYLAZE
Status
Marketed
Status Date
2023-05-03
Original Market Date
2023-05-03
Din
02530406
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intramuscular
Schedule
Prescription , Schedule D
Ahfs
44:00.00
Atc Original
L01XX02 ASPARAGINASE
Atc Name
l 01 xx 02
Aig Number
0164041001
Company Name
JAZZ PHARMACEUTICALS IRELAND LIMITED
Company Address
5th Floor, Waterloo Exchange, Waterloo Rd., Dublin, Dublin, Ireland, D04 E5W7
Company Detail Path
/organization/jazz-pharmaceuticals-ireland-limited
Company Information
Pharmaceutical Company Name
JAZZ PHARMACEUTICALS IRELAND LIMITED
Country Name
Ireland
City Name
dublin,country_ie
Address
5th Floor Waterloo Exchange
Active Ingredients
CRISANTASPASE
10 MG / 0.5 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
29251e4d80f51d93
Type
Standard
Back to Health Canada Approvals